Monday, January 27, 2020
Home Medical Cannabis Partners Global medical cannabis leader across five continents

Global medical cannabis leader across five continents

Tilray (Nasdaq: TLRY) is a global leader in medical cannabis research, cultivation, processing and distribution. We aspire to lead, legitimise and define the future of our industry by building the world’s most trusted cannabis company.

A proud pioneer, we are the first GMP-certified medical cannabis producer to supply cannabis flower and extract products to tens of thousands of patients, physicians, pharmacies, hospitals, governments and researchers on five continents.

Tilray’s experience is unmatched worldwide. Our team of 240+ professionals in seven countries serves thousands of patients around the globe. Our 60,000-square foot flagship cultivation facility in British Columbia, Canada, is among the most advanced in the world.

The Tilray European Union Campus, centred on the Biocant Life Sciences and Biotechnology Research Park in Cantanhede, Portugal, is a €20 million investment to further Tilray’s position as Europe’s leading supplier of GMP medical cannabis extract and dried products.

We are committed to scientific research that leads to an improved quality of life, partnering with leading hospitals and universities to advance the clinical applications of cannabinoids.

The history and future of medical cannabis research

The use of cannabis dates back almost 5,000 years. In this century, this year, we are witnessing a dramatic increase in interest in the therapeutic properties of cannabis and phytocannabinoids.

A growing body of preclinical and anecdotal evidence mandates further clinical research into the many potential applications of medical cannabis and cannabinoid therapy in the treatment conditions, including but not limited to pain, nausea, epilepsy, multiple sclerosis, essential tremor and cancer.

Tilray is committed to advancing the understanding of the therapeutic value and risks of cannabinoid-based medicines. We are one of the few medical cannabis companies globally that invests resources into clinical research and clinical data-driven product development.

We acknowledge our responsibility to medical cannabis research and production and aim to contribute to the body of clinical data that will inform best treatment practices and address an urgent need for improving the quality of life of our patients and their families.

  • Cannabinoid products for oral or pulmonary administration
  • Finished cannabinoid formulations
  • Standardized herbal cannabis products
  • Active substances
  • Investigational drug products (compliant with ICH guidelines)
  • Bulk and custom supplies for qualified third parties
  • Epilepsy, Cancer, Autism, Pain, Essential tremor
  • Developing specific cannabinoid profiles for study drugs based on clinical data;
  • Generating relevant pharmacokinetic parameters of study drugs;
  • Establishing and maintaining a pharmacovigilance database; and
  • Launching partnerships with experts in relevant disease areas.

Profile in Pan European Networks: Health, issue 2
Inside Front Cover in Health Europa Quarterly – Issue 5
Profile in Health Europa Quarterly, issue 5
inspired Front Cover in Health Europa Quarterly – Issue 7

Partner Special Reports

Partner eBooks

TILRAY: the medical cannabis research global leader

Medical cannabis is rapidly gaining momentum across the globe, and Tilray Inc. is pioneering the production, research, and distribution of medical cannabis. This ebook explores...

Exploring medical cannabis distribution across Europe

The medical benefits of cannabis are well documented, and Tilray is a company that strives to distribute cannabinoid medication to more patients Tilray is a...

Pin It on Pinterest